SEPARATION AND GENERAL RELEASE AGREEMENTSeparation and General Release Agreement • March 18th, 2019 • Innovate Biopharmaceuticals, Inc. • Pharmaceutical preparations • North Carolina
This SEPARATION AND GENERAL RELEASE AGREEMENT (the “Agreement”) is made and entered into between Innovate Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Christopher P. Prior, Ph.D. (“Executive”). Throughout the remainder of the Agreement, the Company and Executive may be collectively referred to as “the parties.”
CONSULTING AGREEMENTConsulting Agreement • March 18th, 2019 • Innovate Biopharmaceuticals, Inc. • Pharmaceutical preparations • North Carolina
This CONSULTING AGREEMENT (this “Agreement”) is entered into as of February 19, 2019 (the “Effective Date”), by and among, Innovate Biopharmaceuticals, Inc. a Delaware corporation, headquartered in North Carolina (the “Company”), and Christopher P. Prior, Ph.D. (“Consultant”). For purposes of this Agreement, the Company and Consultant may be referred to individually as a “Party” and collectively as the “Parties.”
SEPARATION AND GENERAL RELEASE AGREEMENTSeparation and General Release Agreement • March 18th, 2019 • Innovate Biopharmaceuticals, Inc. • Pharmaceutical preparations • North Carolina
This SEPARATION AND GENERAL RELEASE AGREEMENT (the “Agreement”) is made and entered into between Innovate Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and June S. Almenoff, MD, PhD (“Executive”). Throughout the remainder of the Agreement, the Company and Executive may be collectively referred to as “the parties.”
AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 18th, 2019 • Innovate Biopharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment to the Amended and Restated Employment Agreement (“Amendment”) is executed on the 18th day of February, 2019 (the “Effective Date”) by and between Innovate Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Sandeep Laumas, MD (the “Executive”). The Executive and the Company may be referred to herein as a “Party” or collectively as the “Parties.”
